← Human Trials & Peer-Reviewed Studies
Reduction of Parenteral Nutrition and Hydration Support and Safety With Long-Term Teduglutide Treatment in Patients With Short Bowel Syndrome-Associated Intestinal Failure: STEPS-3 Study
Plain-language guide to PMID 29761915 (2018): open-label randomized controlled trial study of Teduglutide (GLP-2 analog) in 3, patients.
Key Facts
- PMID
- 29761915
- Journal
- Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition
- Year
- 2018
- Study type
- Randomized Controlled Trial
- Authors
- Seidner DL et al. (6 authors)
- DOI
- 10.1002/ncp.10092
- Registered trial
- NCT01560403
What This Study Did, in Plain Language
What Was Tested
Researchers studied Teduglutide (GLP-2 analog) in this randomized controlled trial publication.
Who Took Part
The study group was 3, patients.
By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.
Baseline was the start of TED treatment, in either STEPS or STEPS-2.
At the end of STEPS-3, patients treated with TED in both STEPS and STEPS-2 (TED-TED) received TED for ≤42 months, and patients treated with TED only in STEPS-2 (no TED treatment [NT]/PBO-TED) received TED for ≤36 months.
How the Study Was Run
The design is described as randomized, open-label and placebo-controlled.
The patients were allocated by chance, so the Teduglutide (GLP-2 analog) group and the comparison group should start out alike.
Nothing was hidden in this open-label Teduglutide (GLP-2 analog) study: the patients and staff both knew the treatment.
Some patients received a placebo instead of Teduglutide (GLP-2 analog), giving a reference point.
What Was Measured
PubMed files the paper under topics including Fluid Therapy, Gastrointestinal Agents, Intestinal Diseases, Intestines, Parenteral Nutrition, Peptides and Short Bowel Syndrome.
Author keywords: glucagon-like peptide-2, intestinal failure and teduglutide.
What This Means in Plain Language
The paper is a randomized, open-label and placebo-controlled study of Teduglutide (GLP-2 analog) in 3, patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2018 (Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition), a journal based in United States.
More context: the Teduglutide (GLP-2 analog) compound page.
Our Notes on the Compound
Teduglutide (GLP-2 analog): A GLP-2 analog approved for short bowel syndrome (Gattex/Revestive); it helps the remaining gut absorb more and lowers IV nutrition needs.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.